IP Library Granted Patent US 10,668,173
Granted Patent B2
US 10,668,173 · App. 16/445,352 · Granted Jun 2, 2020

Compositions and methods for the expression of CRISPR guide RNAS using the H1 promoter

Inventors: Vinod Jaskula-Ranga (Cambridge, MA); Donald Zack (Baltimore, MD)
Assignee: The Johns Hopkins University
A61K48/0066C12N15/111C12N15/1138C12N15/63C12N15/85C12N15/86C12N15/8616C12N15/907C07K2319/10C07K2319/60C12N2310/10C12N2310/20C12N2330/51C12N2750/14133C12N2750/14143C12N2830/205C12N2830/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,173
App. No.
16/445,352
Granted
Jun 2, 2020
Kind
B2
Abstract

The presently disclosed subject matter provides compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter. In particular, compositions and methods are provided for the use of the H1 promoter to express CRISPR guide RNA (gRNA) with altered specificity of the 5′ nucleotide, as well as use of the H1 promoter sequence as a bidirectional promoter to express Cas9 nuclease and the gRNA simultaneously. Compositions and methods are also provided for the expression and regulation of gRNA expression in vivo through the use of RNA ribozymes and regulatable aptazymes.

Claims (10)

1. A non-naturally occurring CRISPR system comprising a single vector comprising a bidirectional promoter, wherein the bidirectional promoter comprises:

a) control elements that provide for transcription in one direction of at least one nucleotide sequence encoding a CRISPR system guide RNA (gRNA), wherein the gRNA hybridizes with a target sequence of a nucleic acid; and

b) control elements that provide for transcription in the opposite direction of a nucleotide sequence encoding a RNA-directed nuclease,

wherein the gRNA targets and hybridizes with the target sequence and directs the RNA-directed nuclease to the nucleic acid molecule.

2. The system of claim 1 , wherein the target sequence comprises the nucleotide sequence AN 19 NGG, GN 19 NGG, CN 19 NGG, or TN 19 NGG.

3. The system of claim 1 , wherein the RNA-directed nuclease is a Cas9 protein.

4. The system of claim 1 , wherein the target sequence of the nucleic acid is in a cell.

5. The system of claim 4 , wherein the Cas9 protein is codon optimized for expression in the cell and/or is a Type-II Cas9 protein.

6. The system of claim 4 , wherein the cell is a eukaryotic cell optionally selected from the group consisting of (i) a mammalian cell, (ii) a human cell, and/or (iii) a retinal photoreceptor cell.

7. The system of claim 1 , wherein expression of one or more gene products is decreased.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 11, 2020
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052625/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2020
From: JASKULA-RANGA, VINOD; ZACK, DONALD
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 052450/0814 →
Continuity (5)
Continuation 15864715 · Jan 8, 2018
Division 14951240 · Nov 24, 2015
Continuation PCTUS2015035964 · Jun 16, 2015
Provisional Application 62012802 · Jun 16, 2014
Related Publication 20190365928A1 · Dec 5, 2019